Ploglimet Extended Release Tablet 5/500 mg
Dapagliflozin citric acid 7.35mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Korea Prime Pharmaceuticals Co., Ltd.
MFDS item code 202204059 · Approved 2022.11.10
Improves glycemic control in adults with type 2 diabetes mellitus
This medication is used in combination with dapagliflozin and metformin to complement dietary and exercise therapy primarily for controlling blood sugar in adult patients with type 2 diabetes. It is particularly administered to patients whose blood sugar is not adequately controlled and who have cardiovascular disease or risk factors. For safety regarding cardiovascular events, please refer to professional information. This medication helps with effective blood sugar control and contributes to the overall health management of patients, used for blood sugar improvement.
The dose of this drug should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This drug is generally administered once daily with the evening meal. The maximum dose of this drug is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as 2 tablets of 5mg/1000mg. Patients with no prior experience of diabetes drug therapy who have inadequate glycemic control with monotherapy: When used as initial therapy in patients with no prior experience of diabetes drug therapy, the recommended starting dose of this drug is 1 tablet of 5mg/500mg or 10mg/500mg once daily. Titrate the dose gradually to reduce gastrointestinal adverse reactions associated with metformin. For patients receiving metformin, the recommended dose of dapagliflozin is 10mg once daily, and the dose of this drug should provide the dose of metformin currently being taken or an appropriate dose therapeutically close to it. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted appropriately. For patients switching from combination therapy with dapagliflozin and metformin to this drug, the dose of this drug may be initiated at the doses of dapagliflozin and metformin previously administered. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted appropriately. When this drug is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. The safety and efficacy of this drug have not been specifically evaluated in patients switching to it from another glucose-lowering agent. Because any change may cause a change in glycemic control, all changes in the treatment of patients with type 2 diabetes should be made under careful monitoring. This drug should be swallowed whole and must never be crushed, cut, or chewed. Occasionally, inactive ingredients in this drug may be excreted in the stool as a soft, hydrated mass resembling a tablet. Renal impairment No dose adjustment is necessary in patients with mild renal impairment. For patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or more and less than 60 mL/min/1.73 m2 who do not have other conditions that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this drug, is 500mg once daily, and the maximum daily dose is 1000mg. Administration of this drug is not recommended in patients with an eGFR less than 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) falls below 45 mL/min/1.73m2, administration of this drug should be discontinued immediately. Renal function should be assessed every 3~6 months. Elderly patients Metformin is excreted by the kidneys, and renal function is more likely to be decreased in elderly patients; therefore, this drug should be used with caution as age increases (see Precautions for Use, 9. Administration to Elderly Patients).
This medication is used for the treatment of diabetes and should not be used in patients with poor kidney function or acute illness. While taking this medication, severe hypoglycemia or lactic acidosis can occur rarely, so if symptoms appear, immediate consultation with a doctor is necessary. It is especially safe not to administer this medication to patients with impaired kidney function, those in a dehydrated state, patients with cardiovascular issues, patients with liver dysfunction, and women who are pregnant or breastfeeding. The risk of hypoglycemia may increase when this medication is taken in conjunction with insulin or sulfonylureas, so dosage adjustments may be required. During treatment, symptoms of decreased fluid volume or hypotension may occur, making it important to regularly monitor blood pressure and kidney function. Additionally, genital infections or urinary tract infections may arise, so prompt treatment is needed when infection symptoms occur. This medication may decrease vitamin B12 levels, so monitoring vitamin B12 concentrations during long-term use is advisable. Excessive alcohol intake may increase the risk of side effects from this medication, so alcohol should be avoided during use. If undergoing surgery or contrast examinations, this medication should be temporarily discontinued for a certain period, and resumption should occur only after confirming normal kidney function. Elderly patients or those with decreased kidney function must have dosage adjustments and close monitoring of kidney function. While taking this medication, dizziness or hypoglycemia symptoms may occur, so caution is advised when driving or operating machinery. Keep out of reach of children and store in the original container to maintain the drug's quality and safety.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to prevent air or moisture entry, ideally at room temperature between 1 degree Celsius and 30 degrees Celsius. Storing it this way helps to maintain the medication's effectiveness over time.
Orange, biconvex, egg-shaped film-coated tablet
30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Dapagliflozin citric acid 7.35mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Korea Prime Pharmaceuticals Co., Ltd.
CombinationDapagliflozin citric acid 14.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
HK Inno.N Co., Ltd.
CombinationDapagliflozin citric acid 7.35mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
HK inno.N Co., Ltd.
Dapagliflozin citric acid 14.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Poonglim Pharmaceutical Co., Ltd.
Dapagliflozin citric acid 7.35mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Punglim Muhak Co., Ltd.
CombinationDapagliflozin citric acid 14.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Korea Prime Pharmaceutical Co., Ltd.
Dapagliflozin citric acid 7.35mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Korea Prime Pharmaceutical Co., Ltd.
CombinationDapagliflozin citric acid 14.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
KS Pharm Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.